FDA’s 5 guidance documents provide details for drug development for neurological conditions such as ALS and Alzheimer’s disease

FDA approves Erleada (apalutamide), first treatment for non-metastatic, castration-resistant prostate cancer

FDA authorizes marketing of first blood test to aid in the evaluation of concussion in adults; new quick testing option to help reduce need for CT scans, radiation exposure for patients

FDA permits marketing of clinical decision support software for alerting providers of a potential stroke in patients

Statement from FDA Commissioner Scott Gottlieb, M.D., on Administration’s request for new FDA funding to promote innovation and broaden patient access through competition

FDA announces on groundbreaking approval and interagency approach to bring stable supply of critical medical imaging isotope to the U.S.

FDA and NRC today took important steps to ensure a stable and secure supply of a critical radioactive imaging product used to detect potentially life-threatening diseases

FDA statement on scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse

One part of the Food and Drug Administration’s mission is to ensure the safety of electronic products that emit radiation, like televisions and cell phones. These types of products are part of Americans’ daily life and we take our duty to protect consumers with the utmost gravity. With cell phones, we have relied extensively on a myriad scientific evidence developed over many years to help inform our regulatory thinking. Although the Federal Communications Commission (FCC) sets the standard for radiofrequency energy exposure limits from cell phones, the FCC relies on the FDA and other health agencies for scientific expertise and input regarding those standards.

FDA provides update on ongoing efforts to mitigate impact of saline shortages and monitor other critical products during flu season